CD19 and cancer: In the above-mentioned study, CAR-T cells simultaneously expressing a first-generation, high-affinity anti-CD19 CAR and an anti-PSMA CCR eradicated not only double positive (CD19+PSMA+) cancers, but also CD19+PSMA- ones.